

Mouse granzyme K has pro-inflammatory potential

LT Joeckel^{1,2,3,4,5}, R Wallich⁶, P Martin^{1,10}, D Sanchez-Martinez⁷, FC Weber^{5,8}, SF Martin⁸, C Borner^{2,4}, J Pardo^{1,7}, C Froelich⁹ and MM Simon^{*1}

Granzymes (gzms) are key components of T-killer (Tc) cells believed to mediate pro-apoptotic activities. Recent evidence suggests that gzms also possess non-cytotoxic activities that contribute to host defense. In this study, we show that Tc cells from lymphocytic choriomeningitis virus (LCMV)-infected wild-type (wt) and gzm A/B-deficient mice express similar levels of gzmK protein, with both mouse strains efficiently controlling infection. GzmK, in recombinant form or secreted by *ex vivo*-derived LCMV-immune gzmAxB^{-/-} Tc cells, lacks pro-apoptotic activity. Instead, gzmK induces primary mouse macrophages to process and secrete interleukin-1 β , independent of the ATP receptor P2X₇. Together with the finding that IL-1Ra (Anakinra) treatment inhibits virus elimination but not generation of cytotoxic Tc cells in wt mice, the data suggest that Tc cells control LCMV through non-cytotoxic processes that involve gzmK.

Cell Death and Differentiation (2011) 18, 1112–1119; doi:10.1038/cdd.2011.5; published online 11 February 2011

The cytotoxic cell granule secretory pathway is considered indispensable for eliminating tumor and virally infected cells. The underlying process is mediated by the pore-forming protein, perforin (perf), which delivers a family of serine proteases, namely the granzymes (gzms), to cells, presumably targeted for destruction. The gzms have been characterized by DNA sequencing of counterparts in the mouse, rat and humans and by the availability of recombinant proteins for functional and structural analyses.^{1,2} On the basis of their transfer into target cells and secretion extracellularly, gzms were originally anticipated to act both intracellularly and mediate extracellular proteolytic events.³ However, the discovery that isolated gzms induced apoptosis in the presence of perf^{4,5} encouraged the notion that proteases acted primarily as death effectors.

Human (Hu)gzmA was reported to induce pro-inflammatory cytokines in human monocytes and mouse macrophages more than 10 years ago,⁶ which may be due to processing of interleukin (IL)-1.⁷ The significance of this observation was not appreciated until recently when (Hu) and mouse (Mo)gzms were observed to lack cytotoxic activity *in vitro*,⁸ except under very restricted conditions.^{8,9} In the absence of the apparent cytotoxicity mediated by (Hu) and (Mo)gzms, the possibility that the protease might act *in vivo* to induce pro-inflammatory cytokines was re-evaluated. In this regard, isolated (Hu) and (Mo)gzms, as well as human natural killer (NK) and mouse T-killer (Tc) cells secreting the protease were shown to induce

human monocytic cells or pre-sensitized mouse peritoneal macrophages (PEM \emptyset s), respectively, to express and secrete pro-inflammatory cytokines IL-1 β , tumor necrosis factor (TNF)- α and/or IL-6.⁸ In addition, caspase-1 inhibition was found to reduce (Hu)gzmA-induced IL-1 β and TNF- α secretion by stimulated human monocytes, suggesting that gzmA may be another activator of the inflammasome platform systems.¹⁰ The physiological importance of this phenomenon was then validated by showing that gzmA knockout (ko) mice (gzmA^{-/-}) resist the lethal effects of LPS.⁸ Together with the recent finding that (Mo)gzmM augments TLR4-driven inflammation and endotoxemia,¹¹ these observations set a biological precedent indicating that (Hu/Mo)gzms may have additional functions besides acting as pro-apoptotic mediators.

The highly cationic gzmK from humans and mouse has tryptase-like substrate preference similar to (Hu)gzmA, but the fine specificity is undoubtedly unique.¹² Similar to (Hu)gzmA, the original report indicated that isolated Rat and (Hu)gzms are cytotoxic *in vitro*.¹³ A more recent study has suggested that isolated (Hu)gzmK induces biochemical events similar to (Hu)gzmA in target cells. In this study, (Hu)gzmK processes the nucleosome assembly protein (SET) releasing the DNase NM23H1, which translocates to the nucleus. The apurinic endonuclease 1 is also cleaved by (Hu)gzmK. On the other hand, caspase-3 activation is undetectable.^{14–16} (Hu)gzmK may also cleave the tumor

¹Metschnikoff Laboratory, Max-Planck-Institut für Immunbiologie, Freiburg, Germany; ²Institute of Molecular Medicine and Cell Research (ZBMZ), Albert-Ludwigs-University, Freiburg, Germany; ³GRK1104, Freiburg, Germany; ⁴Spemann Graduate School of Biology and Medicine (SGBM), Albert-Ludwigs-University, Freiburg, Germany; ⁵Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany; ⁶Infectious Immunology INF 305, Institute for Immunology, University of Heidelberg, Heidelberg, Germany; ⁷Department of Biochemistry and Molecular and Cell Biology, University of Zaragoza (ARAID; Aragón I + D Foundation), Zaragoza, Spain; ⁸Department of Dermatology, Allergy Research Group, University Medical Center, Freiburg, Germany and ⁹NorthShore University HealthSystems Research Institute, University of Chicago School of Medicine, Evanston, IL, USA

*Corresponding author: MM Simon, Metschnikoff Laboratory, Max-Planck-Institut für Immunbiologie, Stübweg 51, 79108 Freiburg, Germany.

Tel: + 49 761 23854; Fax: + 49 761 7048055; E-mail: simon@immunbio.mpg.de

¹⁰Current address: Department of Pathology and Immunology, Centre Médical Universitaire, University of Geneva, 1211 Geneva 4, Switzerland.

Keywords: T-killer cell; virus control; orphan granzymes; inflammation

Abbreviations: gzm, granzyme; Hu, human; IL-1 β , interleukin-1 beta; IL-1Ra, IL-1 receptor antagonist (Anakinra); i.p., intraperitoneal; ko, knockout; LCMV, lymphocytic choriomeningitis virus; MEF, mouse embryonic fibroblast; Mo, mouse; NK, natural killer; PEM \emptyset s, peritoneal macrophages; perf, perforin; p.i., post infection; rec., recombinant; SET, nucleosome assembly protein; SLO, streptolysin O; Tc, T-killer cell; wt, wild type

Received 04.6.10; revised 14.12.10; accepted 03.1.11; Edited by J Tschopp; published online 11.2.11

suppressor, p53, thus sensitizing tumor cells for apoptosis induction¹⁷ and may process a vasolin-containing protein, thus contributing to endoplasmic reticulum stress and caspase-independent cytotoxicity.¹⁸ Compared with the proposed cytotoxic role for gzmK, the protease has been found by immunoassays¹⁹ to be elevated in the plasma of patients with sepsis²⁰ and in the bronchoalveolar fluid of patients with asthma and viral pneumonias,²¹ suggesting that gzmK may have additional biological functions.

Perf^{-/-} mice demonstrate the critical role of the granule-secretory pathway in the recovery from lymphocytic choriomeningitis virus (LCMV) infection.²² However, compared with perf, the contribution of gzmA, gzmB and orphan gzms in the host defense against this pathogen is controversial.^{23,24} After intraperitoneal (i.p.) challenge with LCMV, gzmB^{-/-} and gzmAxB^{-/-} mice clear the virus, although somewhat less vigorously than wild-type (wt) mice. A recent study showed that (Mo)gzmK is expressed as mRNA by *ex vivo* LCMV-immune Tc cells, independent of their expression of gzmA and/or gzmB.²⁵ GzmK has been suggested to contribute to the clearance of influenza virus in mice,^{26,27} but overall, the biological function(s) of this gzm family member remains incompletely characterized. The purpose of this report is to re-examine the cytotoxic activity of (Mo)gzmK and, because of its similar substrate specificity to (Hu/Mo)gzmA, to determine whether the protease has pro-inflammatory effects.

Results

LCMV infection in mice is readily controlled in the absence of gzmA and B. Previous studies have demonstrated that although perf is essential for optimal control of LCMV infection,²² both gzmA and B have a marginal role.^{23,24} To verify this supposition, we compared survival and viral titers in mice lacking gzmA and B (gzmAxB^{-/-}) with those without perf and the two gzms (perfxgzmAxB^{-/-}). After challenge with 1×10^5 p.f.u. LCMV-WE, all perfxgzmAxB^{-/-} (9/9) died, but only 1/9 gzmAxB^{-/-} and none of the wt B6 mice succumbed to the virus during the 30-day observation period (Figure 1a). At day 8 after inoculation, hepatic virus titers were similarly increased in WT, as well as in gzmAxB^{-/-} and triple ko mice with somewhat higher levels in ko mouse strains (Figure 1b). However, although the level of virus gradually declined to background levels in gzmAxB^{-/-} and B6 mice, no reduction of virus load was observed in the liver of perfxgzmAxB^{-/-} mice during the entire observation period (Figure 1b). The data are consistent with previous studies²³ emphasizing that the control of LCMV infection, including viral elimination, is strictly dependent on perf but that neither gzmA nor gzmB are obligatory participants.

Gzm K is expressed in LCMV-immune Tc cells from wt and gzmAxB-deficient mice. To test the assumption that other gzms besides gzmA and B might contribute to perf-mediated control of LCMV infection in gzmAxB^{-/-} mice, virus-immune Tc cells (day 8 post infection (p.i.)) were evaluated for the expression of perf and gzm-specific mRNAs and their respective intracellular proteins. As reported previously,²⁵ virus-immune Tc cells from B6,




Figure 1 (a) Survival of wild-type, gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice infected with LCMV-WE. Groups (nine mice each) of B6 (dashed line) or gzmAxB^{-/-} (dotted line) or perfxgzmAxB^{-/-} (line) mice were infected with 1×10^5 p.f.u. LCMV-WE i.p., and survival was monitored for 30 days. (b) LCMV-WE replication in the liver of WT, gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice. Groups of B6, gzmAxB^{-/-} and perfxgzmAxB^{-/-} (18 mice per strain) recipients were infected with 1×10^5 p.f.u. LCMV-WE i.p. Six mice from each group were killed at 8, 12 and 19 days p.i. Virus titers of individual mice were determined by the plaque titer assay as described in the 'Materials and Methods' section. (c) Expression of mRNA in *ex vivo* LCMV-immune CD8-enriched Tc cells from WT, gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice. Total mRNA was isolated from *ex vivo* LCMV-immune CD8-enriched Tc cells (day 8 p.i.) from wild-type, gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice, previously infected with 1×10^5 p.f.u. LCMV-WE i.p. Samples were analyzed by RT-PCR for their expression of transcripts using specific primers for gzmA-G, gzmK, gzmM, Prf1 and Hprt1. (d) Intracellular expression of gzm and perf protein in *ex vivo* LCMV-immune CD8-enriched Tc cells (day 8 p.i.). *Ex vivo* LCMV-immune CD8-enriched Tc cells (day 8 p.i.) of wt, gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice, infected with 1×10^5 p.f.u. LCMV-WE i.p. were analyzed by FACS for intracellular expression of gzmK (blue line) using the respective rabbit anti-K immune serum and the control pre-immune serum (red line)

gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice expressed similar levels of the gzmK transcript and the mRNA for gzmA, gzmB and perf expected for the respective ko mice (Figure 1c). No transcripts for gzmC-G and gzmM were detectable (for gzmM, also see Supplementary Figure 1C). To ensure

that various effector populations expressed the gzmK protein, its presence in CD8⁺ Tc cells of uninfected and LCMV-infected mice (day 8 p.i.) was determined using a recently developed rabbit anti-recombinant (rec.) (Mo)gzmK antibody. Although gzmK was undetectable in Tc cells from non-infected mice, Tc cells from all three infected mouse strains contained similar levels of the protease (Figure 1d). As expected, only Tc cells from LCMV-immune B6 but not from gzmAxB^{-/-} and perfxgzmAxB^{-/-} mice expressed gzmA and gzmB proteins (data not shown).

LCMV-immune Tc cells that express gzmK and lack gzmA and gzmB are non-cytotoxic. To determine whether LCMV-immune gzmAxB^{-/-} Tc cells that primarily expressed gzmK induce apoptosis in mouse embryonic fibroblast (MEF) cells, we measured multiple parameters, including phosphatidylserine (PS) externalization, propidium iodide (PI) uptake, mitochondrial depolarization ($\Delta\Psi_m$) and reactive oxygen species (ROS) generation. Despite the fact that LCMV-immune B6 and gzmAxB^{-/-} mice both readily controlled LCMV infection, only *ex vivo*-derived LCMV-immune B6 Tc cells induced cell death in target cells *in vitro* as defined by the above-mentioned parameters (Figure 2a). On the other hand, LCMV-immune gzmAxB^{-/-} Tc cells were only marginally cytotoxic, whereas LCMV-immune perfxgzmAxB^{-/-} Tc cells were completely inactive. Conversely, LCMV-immune gzmAxB^{-/-} NK cells, which expressed perf and gzmM, but no gzmK, showed residual cytotoxic activity, which was however at least five times lower than that of gzmA^{-/-} mice (Supplementary Figure 1A).

Recombinant (Mo) gzmK and gzmA are not cytotoxic. To compare the cytotoxic potential of isolated rec. (Mo)gzmK with rec. (Mo)gzmA and B, EL4 cells were incubated with increasing concentrations of the proteases (150–1200 nM) delivered by streptolysin O (SLO), and cell death was determined by PI uptake, annexin reactivity (PS exposure),

$\Delta\Psi$ and ROS generation. Although neither (Mo)gzmA nor (Mo)gzmK elicited a cytotoxic response at all concentrations, (Mo)gzmB showed the predicted concentration-dependent induction of cell death (Figure 2b), including cleavage of




Table 1 Amidolytic activity of (Mo)gzmA and (Mo)gzmK on chromogenic substrates

Substrates	gzmA	gzmK
	Specific activity Units/ μ g protein	
Pro-Phe-Arg-pNA	107	115
Tos-Gly-Pro-Arg-pNA	9	120
H-D-Ile-Pro-Arg-pNA	25	31
Bz-Arg-pNA	0	3

caspase-3 (Figure 2c). To ensure that rec. (Mo)gzmA and rec. (Mo)gzmK manifested enzymatic activity and to verify their predicted differences in cleavage specificity,¹² their amidolytic activities were compared against four different chromogenic substrates. Both gzms were proteolytically active, with each exhibiting distinct preferences for the four related chromogenic substrates, especially Tos-Gly-pro-Arg-pNA (Table 1). Finally, a cell survival assay was performed²⁸ to exclude the possibility that gzmK might induce cell death that is undetected by the parameters mentioned above. Re-growth of EL4 cells was unimpaired for targets incubated only with the rec. (Mo)gzmK (1000 nM) or after the protease was delivered by SLO (Figure 2d).

Recombinant (Mo)gzmK induces macrophages to release IL-1 β . Although rec. (Mo)gzmA and rec. (Mo)gzmK have different substrate specificities, we speculated that the tryptase-like activity of (Mo)gzmK might mimic (Mo)gzmA in its capacity to induce pre-activated PEMOs to express and secrete mature IL-1 β . In this regard, rec. (Mo)gzmK was added to LPS-primed PEMOs in the presence or absence of SLO. The delivery of gzmK by SLO induces concentration-dependent processing of pro-IL-1 β , requiring doses >30 nM (Figure 3a and Supplementary Figure 2). SLO alone was also observed to induce detectable, although minor maturation/secretion of IL-1 β (Figure 3a and Supplementary Figure 2). At higher concentrations of gzmK (600 and 1000 nM), the protease alone was sufficient to induce release of IL-1 β to levels observed for cells treated with the gzm and SLO. Finally, the inactive pro-form of rec. (Mo)gzmK did not alter maturation/secretion of IL-1 β (Supplementary Figure 2) eliminating the possibility that the gzm was inducing the cytokine through a non-proteolytic mechanism.

LCMV-immune Tc cells of B6 and gzmAxB^{-/-} mice induce IL-1 β release from wt and P2X₇^{-/-} macrophages. LCMV-immune B6 and gzmAxB^{-/-} Tc cells were added to LPS-primed PEMOs in the presence or absence of LCMV-specific immunogenic peptide, gp33. In the absence of gp33, LCMV-immune B6 and gzmAxB^{-/-} Tc cells induced only marginal processing and release of IL-1 β in PEMOs at an E/T ratio of 5:1. In contrast, gp33-pulsed targets responded to LCMV-immune B6 and gzmAxB^{-/-} Tc cells by secreting substantial amounts of IL-1 β (p17; Figure 3b). To exclude the possibility that Tc cell-induced IL-1 β secretion was due to ATP released from stressed PEMOs,^{29,30} the response of cells from mice lacking the ATP sensor (P2X₇ receptor) was used under similar conditions. Although treatment with ATP (5 mM) did not result in secretion of




Figure 3 (a) Induction of IL-1 β release by rec. (Mo)gzmK. Adherent B6 PEMOs, previously sensitized with thioglycollate *in vivo* and challenged with LPS *in vitro* were incubated with the indicated amounts of gzmK in presence or absence of 0.25 μ g/ml SLO, or ATP as positive control, for 3 h and SNs were subjected to WB analysis using anti-IL-1 β -specific Ab. Aliquots of the following preparations were used as standards for WB analysis: SNs of ATP-sensitized pre-activated B6 PEMOs; SNs of thioglycollate-pre-sensitized and LPS-challenged B6 PEMOs. (b) Induction of IL-1 β release by *ex vivo* CD8 cells expressing gzmK. Thioglycollate-pre-sensitized and LPS-challenged adherent B6 PEMOs were incubated with *ex vivo*-derived LCMV-immune Tc cells from B6 or gzmAxB ko mice at an E/T ratio of 5:1 in the presence or absence of the LCMV-specific peptide gp33. SN was taken after 6 h and subjected to WB analysis using anti-IL-1 β -specific Ab. As control, SN from thioglycollate-pre-sensitized and LPS-challenged B6 PEMOs, and subsequently stimulated with 5 mM ATP, was analyzed accordingly. Aliquots of the following preparations were used as standards for WB analysis: rec. IL-1 β s, p17; SN of ATP-sensitized pre-activated wt B6 PEMOs; SN of wt thioglycollate-pre-sensitized and LPS-activated B6 PEMOs. (c) Induction of IL-1 β release by *ex vivo* CD8 cells expressing gzmK by targets lacking the P2X₇ receptor. Experimental procedure was conducted as described in panel b, but with macrophages from P2X₇^{-/-} mice. Controls were prepared individually for this experiment with P2X₇^{-/-} macrophages (SN of ATP-sensitized pre-activated PEMOs; SN of wt thioglycollate-pre-sensitized and LPS-activated PEMOs)

active IL-1 β , wt and gzmAxB^{-/-} Tc cells readily induced the release of mature IL-1 β from P2X₇-deficient PEMOs to an extent similar to wt PEMOs (Figure 3c).

In vivo treatment of mice with IL-1RA inhibits virus elimination. To explore the possibility that IL- β participates in the control of LCMV infection, B6 mice were treated with IL-1Ra (Anakinra; see the study by So *et al.*³¹) and virus titers were monitored in the liver on days 8, 12 and 19. In contrast to mock-treated and virus-infected B6 mice

(Figure 1b), recipients treated with Anakinra were unable to eliminate LCMV (Figure 4a). This outcome was not due to the absence of activated Tc cells because the ratio of LCMV-specific Tc is comparable for untreated and treated LCMV-infected mice (Figure 4b). Furthermore, LCMV-immune Tc cells taken from the same Anakinra-treated




Figure 4 (a) Anakinra inhibits recovery from LCMV infection. B6 mice received Anakinra before infection (1×10^5 p.f.u. LCMV-WE i.p.) and then on every third day thereafter. Three mice from each group were killed at 8, 12 and 19 days and hepatic viral replication determined. (b) Anakinra-treated mice infected with LCMV express levels of LCMV-specific Tc cells similar to untreated controls. Mice were first treated with Anakinra (200 μ g) 1 day before infection and then every third day. After killing (day 8), splenic CD8 cells were isolated and virus-specific Tc cells were determined by pentamer staining. The livers from these mice were used to generate data reported in panel a. (c) Anakinra-treated and control Tc cells mediate similar apoptotic effects against EL4 cells. Gp-33-pulsed or untreated EL4 target cells were incubated with *ex vivo* LCMV-immune CD8-enriched Tc cells (4 h, 10 : 1). Subsequently, PS exposure on the plasma membrane (annexin-V-FITC) and PI uptake were analyzed by flow cytometry

mice showed pro-apoptotic activity similar to mock-treated Tc (Figure 4c).

Discussion

The observation that *perf*^{-/-} mice die from LCMV infection clearly indicates that the pore-forming protein *perf* is essential for Tc cell (NK)-mediated control of this virus.²² However, as *perf* functions chiefly to deliver gzms and other granule components into target cells, an understanding of the role(s) of these proteins in the anti-viral response and associated tissue damage is crucial. For example, LCMV is cleared in *gzmA*^{-/-} and *gzmB*^{-/-} mice, although recovery is delayed in the latter compared with wt controls,²⁴ and LCMV-associated hepatitis seems to require the presence of *gzmA* and *gzmB*.²³ We have observed in this study that the course of virus infection was similar, but not identical for *gzmAxB*^{-/-} and B6 mice, indicating that other granule proteins are possible participants.² As Tc cells are essential to control LCMV infection and *gzmK* is expressed in virus-immune *gzmAxB*^{-/-} Tc cells that retain this capacity, one could speculate that *gzmK* together with *perf* may contribute to the host response that results in the elimination of the virus.

Although the molecular basis for a *gzmK*-mediated anti-viral response is uncertain, based on past observations, the tryptase is predicted to clear LCMV by inducing infected cells to undergo apoptosis. By studying the human system, the Fan group has shown that *rec. (Hu)gzmK* elicits multiple pro-apoptotic pathways that could participate in anti-viral immunity. Their laboratory has reported that the *gzm* directly processes Bid, which releases cytochrome *c* and endonuclease G, resulting in the activation of a mitochondrial-dependent cell death pathway, although without caspase-3 activation.¹⁴ *Rec. (Hu)gzmK*, similar to *rec. (Hu)gzmA*, has also been reported to cleave SET, which occurs in association with single-stranded DNA nicks in target cells.¹⁵ Furthermore, *rec. (Hu)gzmK* has been reported to cleave p53 into three products (namely p40, p35 and p13), which apparently possess pro-apoptotic activities. In addition, these fragments are proposed to augment the cytotoxic activity of *gzmK*, although other biological effects cannot be excluded.¹⁷ Finally, *(Hu)gzmK* was shown to cleave a vasolin-containing protein resulting in accelerated endoplasmic reticulum stress and caspase-independent cytotoxicity of tumor cells.¹⁸ In marked contrast, this study demonstrates that *ex vivo*-derived LCMV-immune Tc cells which are positive for *gzmK* but negative for *gzmA* and *gzmB* expressed only marginal pro-apoptotic/cytotoxic activities, especially when measured by sensitive markers that assess plasma membrane and mitochondrial integrity, as well as by a target cell-survival assay. This finding agrees with reports showing that LCMV- and ectromelia-immune *gzmAxB*^{-/-} Tc cells show marginal pro-apoptotic activity.^{25,32,33} More strikingly, *rec. (Mo)gzmK*, like *(Mo)gzmA*,⁸ completely failed to induce cell death at concentrations that suffice for *gzmB*-induced apoptosis. The combined results suggest that *(Mo)gzmK*, through non-cytotoxic processes, might be one component in the complex of molecular events that contribute to the elimination of LCMV. Notably, NK cells from infected *gzmAxB*^{-/-} mice, which did not express *gzmK* as expected

from previous studies,³⁴ showed low but significant cytotoxic activity, which may be due to the expression of *gzmM*. However, the possibility that LCMV infection in these ko mice is controlled by NK cells is less likely, as NK cells have been shown before to be unable on their own to control LCMV infection, even if they fully express the exocytosis pathway.

Offering a major paradigm shift in characterizing the functionality of the granule secretory pathway, we have learned that isolated *(Mo)gzmA* and *ex vivo* virus-immune mouse Tc cells containing *gzmA* induce IL-1 β release from LPS-sensitized PEM ϕ s.^{8,35} As *gzmA* may contribute to host defense by inducing pro-inflammatory cytokines in pathogen-infected cells targeted by the granule secretory process, we speculated that *(Mo)gzmK*, displaying a tryptase-like activity similar but not identical to *(Mo)gzmA*,¹² might also be an inducer of pro-inflammatory cytokines. Accordingly, we show in this study for the first time that nanomolar concentrations of *rec. (Mo)gzmK* and LCMV-immune Tc containing *gzmK*, but neither *gzmA* nor *gzmB*, induce the maturation and secretion of IL-1 β in LPS-sensitized PEM ϕ s. The fact that *gzmK* displays a highly restricted substrate specificity that only partially overlaps with *(Mo)gzmA*,¹² suggests that *(Mo)gzmK* may augment *(Mo)gzmA*-induced pro-inflammatory processes by differentially cleaving the same or distinct specific substrates. This assumption is supported by the fact that B6 Tc cells, which express *gzmA* and *gzmK* together with *gzmB*, have a greater capacity than *gzmAxB*^{-/-} Tc cells to induce IL-1 β release from LPS-sensitized PEM ϕ s.

Pro-IL-1 β is produced in response to danger or pathogen-associated molecular patterns such as LPS and can be processed to the mature and secreted cytokine by the NLRP3 inflammasome, a caspase-1-activating cytosolic protein complex.³⁰ The NLRP3 inflammasome is not only activated by numerous stimuli such as bacterial toxins and uric acid crystals but also by extracellular ATP released from stressed or damaged cells. This endogenous danger signal is sensed by the purinergic receptor P2X₇, a ligand-gated ion channel.²⁹ Our results show that the release of IL-1 β of PEM ϕ s induced by B6 and *gzmAxB*^{-/-} Tc was not affected by the absence of the P2X₇ receptor. This result suggests that Tc-induced IL-1 β processing is not due to ATP derived from damaged target cells, and therefore, strengthening the concept that pro-inflammatory gzms such as *gzmK* participate in inflammasome activation.

Overall, the data show that neither *gzmA* nor *gzmB* are essential to control LCMV infection in mice. This observation, which supports previous work,^{23,24} is intriguing especially when combined with results of this study indicating that *ex vivo* anti-LCMV Tc cells from *gzmAxB*^{-/-} mice exhibit markedly reduced cytotoxicity *in vitro*. Similar to these Tc cells that primarily contain *(Mo)gzmK*, *rec. (Mo)gzmK* delivered by SLO also failed to mount the anticipated cytotoxic response. Thus, the anti-viral effects of *in vivo* anti-LCMV Tc cells does not correlate with their *in vitro* cytolytic activity, but rather is mediated through non-cytotoxic pathways, such as inflammasome activation or uncharacterized biological effects.³⁶

The possibility that *(Mo)gzmK* induces IL-1 β release which aids in LCMV clearance is further supported by the observation that mice treated with Anakinra are unable to control replication, even though the ratio of LCMV-immune Tc cells

generated under these conditions, including their cytotoxic potential was similar to that of untreated infected B6 mice (Figures 4b and c). These findings differ from a recent study in which IL-1R^{-/-} mice, challenged with influenza virus, were unable to generate virus-specific Tc.³⁷ This discrepancy may be due to the different approaches used to reduce IL-1 β in the two systems. In IL-1R^{-/-} mice, IL-1 β is expected to be unable to mediate its myriad biological effects through IL-1R including the induction of Tc. The blockade produced by Anakinra is predicted to be incomplete allowing the induction of virus-specific Tc cells, but curtailing the anti-viral activity capacity of the cytokine during the effector phase of the host response. Although (Mo)gzmK, similar to (Hu)gzmH,³⁶ might mediate direct antiviral effects that contribute to viral clearance, together the evidence supports the existence of a (Mo)gzmK-induced pro-inflammatory pathway that controls intracellular pathogens.

In comparison with (Mo)gzmK, isolated (Hu)gzmK has been reported to be directly cytotoxic *in vitro* when delivered by SLO or adenoviral particles.¹⁴ However, others have been unable to demonstrate the rec. (Hu)gzmK is cytotoxic *in vitro* when delivered by SLO to Hela cell targets at concentrations reaching 1000 nM (personal communication, Niels Bovenschen). Using intact Tc primarily containing (Mo)gzmK, we have verified that (Mo)gzmK delivered *in vitro* is not cytotoxic. A similar approach will be necessary to reconcile whether (Hu)gzmK is cytotoxic.

Future studies that use gzmK-deficient mice will be necessary to verify whether LCMV infection is controlled by gzmK and/or by other granule-associated components and whether the putative anti-viral activity of gzmK is linked to the induction of pro-inflammatory cytokines in macrophage subsets or to other non-cytotoxic pathways. In contrast to LCMV, other viruses such as ectromelia depend on cytolytic gzmB.³⁸ Thus, depending on the virus and the tissue distribution of infection, Tc cells may use individual gzms to kill infected targets and use one or more of the gzms to disrupt their life cycle by non-cytolytic means.

Materials and Methods

Mouse strains. The following strains were maintained at the Max-Planck-Institut für Immunobiologie, Freiburg (Germany): C57BL/6 (B6; wt); strains deficient for gzmA (gzmA^{-/-}), gzmA and gzmB (gzmAxgzmB^{-/-}) and perf, gzmA and gzmB deficient (perfgzmAxgzmB^{-/-}), were bred on the B6 background.²³ Mice deficient for P2X₇ (P2X₇^{-/-}) were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Animal studies were conducted in accordance with the ethics guidelines of the Federation of European Laboratory Animal Science Association.

Virus. The LCMV (strain WE), kindly provided by O. Utermöhlen (Cologne, Germany) was expanded in L929 fibroblasts, as described previously.²⁵ The virus-specific epitope gp33 (kavynfatatc; Neosystem, Strasbourg, France) for H-2D^b was used for target labeling in cytotoxicity assays.²⁵

Disease model. Mice were infected i.p. with 10⁵ p.f.u. of LCMV-WE according to established protocols.^{25,39}

IL-1Ra (Anakinra) treatment. Mice were injected 1 day before infection with 10⁵ p.f.u. LCMV-WE with 200 μ g IL-1Ra (Anakinra, Kineret Amgen, Breda, The Netherlands) in 200 μ l PBS and from then on every third day with the same dose until the end of experiment.³¹

Virus titers. Aliquots of liver tissues were homogenized and used for determination of virus titers as described elsewhere.³⁹

Generation of ex vivo CD8⁺ cells. On day 8 p.i., CD8⁺ cells were positively selected from the spleen using α -CD8-MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) with an autoMACS (Miltenyi Biotec) and resuspended in MEM/5% FCS before use in cytotoxic assays as described previously.²⁵ Detection of LCMV-immune CTL was conducted by double staining with CD8 antibody (BD Pharmingen, San Diego, CA, USA; clone 53-67) and gp33-labeled pentamers (Prolimmune, Oxford, UK) as described previously.³²

Cell lines, cell culture and reagents. The mouse cell lines 1.3E6 (Tc cell line) and EL4.F15 (thymoma), and MEF cell lines were cultured as described previously.^{25,40} rec. (Mo)gzmK was produced in *Escherichia coli* B834 (DE3) using the pET-21a vector and purified as described previously.⁴¹ Rabbit immune serum specific for (Mo)gzmK was generated as described for (Mo)gzmB.²⁸

Analysis of pro-apoptotic processes. Cell death induced by ex vivo CD8-enriched Tc cells or by isolated gzms in the presence or absence of SLO, was analyzed as described previously.³² In brief, target cells were pre-treated with LCMV-immunodominant peptide gp33 for 2 h before incubation with ex vivo-derived LCMV-immune CTL at 10:1 E/T cell ratio for 4 h at 37°C, 7% CO₂. Alternatively, target cells were incubated with the indicated concentration of rec. gzms with or without SLO for 4 h. Subsequently, different apoptotic parameters were tested in the target population (CD8⁺) by FACS using a FACSCalibur (BD Pharmingen) and FLOWJO (Ashland, OR, USA) software as described previously.^{3,25} In short, for the analysis of cell membrane and mitochondrial membrane perturbations. PS exposure and PI uptake were analyzed by FACS using the annexin-V-FITC kit obtained from BD Pharmingen. Mitochondrial membrane potential was measured with the fluorescent probe 3,3'-dihexyloxacarbocyanine iodide (DiOC₆(3); (Molecular Probes, Eugene, OR, USA) and ROS generation with 2-hydroxyethidium (Molecular Probes). Furthermore, cell populations were analyzed for cell surface markers and intracellular gzm expression as described elsewhere,⁴⁰ analyzed by FACS using a FACSCalibur (BD Pharmingen) and FLOWJO software.

Survival assay. Survival of target cells after their incubation with rec. (Mo)gzmK in the presence and absence of SLO was analyzed as described previously.⁴² In brief, target cells were incubated with 1000 nM rec. (Mo)gzmK in the presence or absence of SLO for 4 h. Thereafter, ³H-thymidine was added and cells were incubated for 10 h at 37°C, 5% CO₂, without removing rec. (Mo)gzmK and SLO. Subsequently, cells were harvested and target cell survival was quantified by ³H-thymidine incorporation as described previously.⁴² This assay produces similar results as clonogenic survival assays in agar plates.²⁵

Enzymatic assays. Amidolytic activity of gzms using the following chromogenic substrates (Bachem, Weil am Rhein, Germany) was performed as described previously:⁴³ Bz-Arg-pNA, H-D-Pro-Phe-Arg-NA, Ac-Ile-Glu-Pro-Asp-pNA and Tos-Gly-Pro-Arg-pNA.

RT-PCR. Total RNA was extracted from up to 5 \times 10⁶ ex vivo CD8⁺ cells, using the QIAshredder spin columns, the RNAeasy mini kit and the RNase-free DNase kit (all from Qiagen, Hilden, Germany) according to the manufacturer's instructions, and specific transcripts were amplified. The sense/antisense primers for *gzmA*, *gzmC*, *gzmD*, *gzmE*, *gzmF*, *gzmG* and *Hprt1* are described in the studies by Martin *et al.*⁴⁰ and Revell *et al.*⁴⁴ respectively. Sense/antisense primers for *gzmB*, *gzmK* and *gzmM* are described in the study by Pardo *et al.*²⁵ Primers for *perf* are described in the study by Balkow *et al.*²³

IL-1 β release assay. B6 mice were injected i.p. with 2 ml 4% thioglycollate (Sigma, Steinheim, Germany) in LPS-free water, 3 days before removal of PEMOs. On day 3 p.i., mice were killed and their peritoneum was washed with 10 ml of PBS to collect PEMOs. Cell suspension was washed, and 8 \times 10⁵ cells/well were plated in a 12-well plate (500 μ l volume/MEM without FCS) and incubated for 1 h at 37°C, 5% CO₂. Subsequently, PEMOs were sensitized with 100 ng/ml LPS (*Salmonella minnesota* R595) and incubated for 2 h at 37°C, 5% CO₂. Thereafter, the supernatant was discarded and PEMOs were challenged either with LCMV-immune ex vivo Tc cells or with rec. gzms (300 μ l volume/MEM without FCS) in the presence or absence of SLO, for 4–6 h at 37°C, 5% CO₂.

Western blot analysis. The inactive and active form of caspase-3, as well as actin and IL-1 β was determined by western blotting under reducing conditions. Rabbit polyclonal anti-human caspase-3 IgG (active and inactive) was obtained from Cell Signaling Technology (Danvers, MA, USA), mouse anti-actin IgG was from MP Biomedicals (Aurora, OH, USA) and goat anti-IL-1 β was obtained from R&D Systems (Minneapolis, MN, USA). Blots were then stained with horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-rabbit IgG or goat anti-mouse IgG (all purchased from Jackson ImmunoResearch Laboratories Inc., Suffolk, UK), followed by enhanced chemiluminescence (ECL Western Blotting Analysis System; GE Healthcare, München, Germany).

Conflict of interest

The authors declare no conflict of interest.

Acknowledgements. This study was supported in part by the Excellence Initiative of the German Federal and State Governments (GSC-4, Spemann Graduate School) and by the Centre for Biological Signaling Studies (bioss, EXC 294), both supported by the Excellence Initiative of the German Federal and State Governments, and the Deutsche Forschungsgemeinschaft (BO-1933 and GRK1104). CF was supported through 5RO1AI04494-03. JP was supported by Grant SAF2008-02139 from the Ministerio de Ciencia e Innovación (Spain) and Grant PI076/08 by Gobierno de Aragón. We thank Anton Grubisic, Aynur Ekiciler, Thomas Stehle, Bettina Hartmann, Inga Clausen, Dominik Wieland, Jüri Habicht and Christiane Brenner for their expert technical assistance. We also thank Sucharit Bhakdi for his generous gift of streptolysin O and Marina Freudenberg and Chris Galanos for providing LPS.

1. Barry M, Bleackley RC. Cytotoxic T lymphocytes: all roads lead to death. *Nat Rev Immunol* 2002; **2**: 401–409.
2. Grossman WJ, Revell PA, Lu ZH, Johnson H, Bredemeyer AJ, Ley TJ. The orphan granzymes of humans and mice. *Curr Opin Immunol* 2003; **15**: 544–552.
3. Kramer M, Simon MM. Are proteinases functional molecules of T cells? *Immunol Today* 1987; **8**: 140–143.
4. Hayes MP, Berrebi GA, Henkart PA. Induction of target cell DNA release by the cytotoxic T lymphocyte granule protease granzyme A. *J Exp Med* 1989; **170**: 933–946.
5. Shi L, Kraut RP, Aebersold R, Greenberg AH. A natural killer cell granule protein that induces DNA fragmentation and apoptosis. *J Exp Med* 1992; **175**: 553–566.
6. Sower LE, Froelich CJ, Allegretto N, Rose PM, Hanna WD, Klimpel GR. Extracellular activities of human granzyme A. Monocytic activation by granzyme A versus alpha-thrombin. *J Immunol* 1996; **156**: 2585–2590.
7. Irmiler M, Hertz S, MacDonald HR, Sadoul R, Becherer JD, Proudfoot A *et al*. Granzyme A is an interleukin 1 beta-converting enzyme. *J Exp Med* 1995; **181**: 1917–1922.
8. Metkar SS, Menaa C, Pardo J, Wang B, Wallich R, Freudenberg M *et al*. Human and mouse granzyme A induce a proinflammatory cytokine response. *Immunity* 2008; **29**: 720–733.
9. Beresford PJ, Xia Z, Greenberg AH, Lieberman J. Granzyme A loading induces rapid cytolysis and a novel form of DNA damage independently of caspase activation. *Immunity* 1999; **10**: 585–594.
10. Mariathasan S, Monack DM. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. *Nat Rev Immunol* 2007; **7**: 31–40.
11. Anthony DA, Andrews DM, Chow M, Watt SV, House C, Akira S *et al*. A role for granzyme M in TLR4-driven inflammation and endotoxemia. *J Immunol* 2010; **185**: 1794–1803.
12. Bovenschen N, Quadir R, van den Berg AL, Brenkman AB, Vandenbergh I, Devreese B *et al*. Granzyme K displays highly restricted substrate specificity that only partially overlaps with granzyme A. *J Biol Chem* 2009; **284**: 3504–3512.
13. Shi L, Kam CM, Powers JC, Aebersold R, Greenberg AH. Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. *J Exp Med* 1992; **176**: 1521–1529.
14. Zhao T, Zhang H, Guo Y, Fan Z. Granzyme K directly processes Bid to release cytochrome c and endonuclease G leading to mitochondria-dependent cell death. *J Biol Chem* 2007; **282**: 12104–12111.
15. Zhao T, Zhang H, Guo Y, Zhang Q, Hua G, Lu H *et al*. Granzyme K cleaves the nucleosome assembly protein SET to induce single-stranded DNA nicks of target cells. *Cell Death Differ* 2007; **14**: 489–499.
16. Guo Y, Chen J, Zhao T, Fan Z. Granzyme K degrades the redox/DNA repair enzyme Ape1 to trigger oxidative stress of target cells leading to cytotoxicity. *Mol Immunol* 2008; **45**: 2225–2235.

17. Hua G, Wang S, Zhong C, Xue P, Fan Z. Ignition of p53 bomb sensitizes tumor cells to granzyme K-mediated cytolysis. *J Immunol* 2009; **182**: 2152–2159.
18. Guo Y, Chen J, Shi L, Fan Z. Valosin-containing protein cleavage by granzyme K accelerates an endoplasmic reticulum stress leading to caspase-independent cytotoxicity of target tumor cells. *J Immunol* 2010; **185**: 5348–5359.
19. Bade B, Lohrmann J, ten Brinke A, Wolbink AM, Wolbink GJ, ten Berge IJ *et al*. Detection of soluble human granzyme K *in vitro* and *in vivo*. *Eur J Immunol* 2005; **35**: 2940–2948.
20. Rucevic M, Fast LD, Jay GD, Trespalacios FM, Sucov A, Siryaporn E *et al*. Altered levels and molecular forms of granzyme K in plasma from septic patients. *Shock* 2007; **27**: 488–493.
21. Bratke K, Klug A, Julius P, Kuepper M, Lommatzsch M, Sparmann G *et al*. Granzyme K: a novel mediator in acute airway inflammation. *Thorax* 2008; **63**: 1006–1011.
22. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ *et al*. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature* 1994; **369**: 31–37.
23. Balkow S, Kersten A, Tran TT, Stehle T, Grosse P, Museteanu C *et al*. Concerted action of the FasL/Fas and perforin/granzyme A and B pathways is mandatory for the development of early viral hepatitis but not for recovery from viral infection. *J Virol* 2001; **75**: 8781–8791.
24. Zajac AJ, Dye JM, Quinn DG. Control of lymphocytic choriomeningitis virus infection in granzyme B deficient mice. *Virology* 2003; **305**: 1–9.
25. Pardo J, Wallich R, Martin P, Urban C, Rongvaux A, Flavell RA *et al*. Granzyme B-induced cell death exerted by *ex vivo* CTL: discriminating requirements for cell death and some of its signs. *Cell Death Differ* 2008; **15**: 567–579.
26. Jenkins MR, Kedzierska K, Doherty PC, Turner SJ. Heterogeneity of effector phenotype for acute phase and memory influenza A virus-specific CTL. *J Immunol* 2007; **179**: 64–70.
27. Jenkins MR, Trapani JA, Doherty PC, Turner SJ. Granzyme K expressing cytotoxic T lymphocytes protects against influenza virus in granzyme AB(β) mice. *Viral Immunol* 2008; **21**: 341–346.
28. Pardo J, Wallich R, Ebnert K, Iden S, Zentgraf H, Martin P *et al*. Granzyme B is expressed in mouse mast cells *in vivo* and *in vitro* and causes delayed cell death independent of perforin. *Cell Death Differ* 2007; **14**: 1768–1779.
29. Surprenant A, North RA. Signaling at purinergic P2X receptors. *Annu Rev Physiol* 2009; **71**: 333–359.
30. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. *Annu Rev Immunol* 2009; **27**: 229–265.
31. So A, De Smedt T, Revaz S, Tschopp J. A pilot study of IL-1 inhibition by Anakinra in acute gout. *Arthritis Res Ther* 2007; **9**: R28.
32. Pardo J, Bosque A, Brehm R, Wallich R, Naval J, Mullbacher A *et al*. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. *J Cell Biol* 2004; **167**: 457–468.
33. Pardo J, Aguillo JI, Anel A, Martin P, Joeckel L, Borner C *et al*. The biology of cytotoxic cell granule exocytosis pathway: granzymes have evolved to induce cell death and inflammation. *Microbes Infect* 2009; **11**: 452–459.
34. Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. *Annu Rev Immunol* 2008; **26**: 389–420.
35. Froelich CJ, Pardo J, Simon MM. Granule-associated serine proteases: granzymes might not just be killer proteases. *Trends Immunol* 2009; **30**: 117–123.
36. Andrade F, Fellows E, Jenne DE, Rosen A, Young CS. Granzyme H destroys the function of critical adenoviral proteins required for viral DNA replication and granzyme B inhibition. *EMBO J* 2007; **26**: 2148–2157.
37. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. *J Exp Med* 2009; **206**: 79–87.
38. Mullbacher A, Waring P, Tha Hla R, Tran T, Chin S, Stehle T *et al*. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. *Proc Natl Acad Sci USA* 1999; **96**: 13950–13955.
39. Rode M, Balkow S, Sobek V, Brehm R, Martin P, Kersten A *et al*. Perforin and Fas act together in the induction of apoptosis, and both are critical in the clearance of lymphocytic choriomeningitis virus infection. *J Virol* 2004; **78**: 12395–12405.
40. Martin P, Wallich R, Pardo J, Mullbacher A, Munder M, Modolleil M *et al*. Quiescent and activated mouse granulocytes do not express granzyme A and B or perforin: similarities or differences with human polymorphonuclear leukocytes? *Blood* 2005; **106**: 2871–2878.
41. Wilharm E, Pary MA, Friebel R, Tschesche H, Matschiner G, Sommerhoff CP *et al*. Generation of catalytically active granzyme K from *Escherichia coli* inclusion bodies and identification of efficient granzyme K inhibitors in human plasma. *J Biol Chem* 1999; **274**: 27331–27337.
42. Pardo J, Balkow S, Anel A, Simon MM. The differential contribution of granzyme A and granzyme B in cytotoxic T lymphocyte-mediated apoptosis is determined by the quality of target cells. *Eur J Immunol* 2002; **32**: 1980–1985.
43. Simon MM, Hoshutzky H, Fruth U, Simon HG, Kramer MD. Purification and characterization of a T cell specific serine proteinase (TSP-1) from cloned cytolytic T lymphocytes. *EMBO J* 1986; **5**: 3267–3274.
44. Revell PA, Grossman WJ, Thomas DA, Cao X, Behl R, Ratner JA *et al*. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. *J Immunol* 2005; **174**: 2124–2131.

Supplementary Information accompanies the paper on Cell Death and Differentiation website (<http://www.nature.com/cdd>)